Presentation Will Highlight Company’s Two Recent PCT Technology Breakthroughs
South Easton, MA, June 25, 2013 – Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the 4th Annual OneMedForum Emerging Company Finance Conference on Thursday, June 27th at 10:40 am EDT. Mr. Schumacher's presentation will highlight the two breakthroughs in the Company's patented pressure cycling technology ("PCT") platform announced on May 16 and June 4, 2013. The Investor Conference is being held June 26-27 at the Metropolitan Club in New York City.
About OneMedPlace and the OneMedForum New York 2013 Conference
Through news services, radio interviews, video production, and research, OneMedPlace specializes in delivering information to investors covering nanocap, microcap, and private emerging growth companies in the hottest areas of life sciences. OneMedPlace produces weekly newsletter and research reports covering what they believe to be an undervalued sector; they have built a network of investors at all levels of financial and strategic development.
OneMedForum New York 2013 will showcase investment opportunities in approximately 50 fast-growing private and microcap public companies. More than 500 attendees are expected to participate in the 2013 Investor Conference, including venture capitalists, private equity investors, high net-worth individuals, angel investors, family offices, hedge funds, and investment bankers.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.
For more information about PBI and this press release, please click on the following website link:
Richard T. Schumacher, President and CEO, PBI
(508) 230-1828 (T)
Conrad F. Mir, CFO, PBI
(508) 230-1828 (T)
Timothy J. Connor, Managing Director, Benchmark Advisory
(858) 568-7059 (T)
SOURCE Pressure BioSciences, Inc.